Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation

被引：0
|
作者：
Jonassen, I. [1 ]
Hoeg-Jensen, T. [1 ]
Havelund, S. [1 ]
Ribel, U. [1 ]
机构：
[1] Novo Nordisk AS, Malov, Denmark
来源：
JOURNAL OF PEPTIDE SCIENCE | 2010年 / 16卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [11] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    DIABETOLOGIA, 2011, 54 : S423 - S423
  • [12] Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
    Niskanen, Leo
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz-Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine Vang
    Vaag, Allan
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2012, 167 (02) : 287 - 294
  • [13] Insulin degludec - Ultra-Long-Acting Basal Insulin
    Heise, T.
    Merker, L.
    Matthaei, S.
    DIABETES STOFFWECHSEL UND HERZ, 2012, 21 (04): : 231 - 238
  • [14] Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, is independent of hepatic function
    Lyness, W
    Tyler, J
    Lawrence, A
    DIABETES, 2001, 50 : A442 - A442
  • [15] Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart
    Dall, V
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1999, 49 (05): : 463 - 470
  • [16] Pharmacokinetics of the rapid-acting insulin analog, insulin aspart, in rats, dogs, and pigs, and pharmacodynamics of insulin aspart in pigs
    Plum, A
    Agerso, H
    Andersen, L
    DRUG METABOLISM AND DISPOSITION, 2000, 28 (02) : 155 - 160
  • [17] The Experience of our Center in Patients Undergoing Insulin Degludec/Insulin Aspart Co-formulation Therapy
    Altay, Feride Pinar
    Farzaliyeva, Aydan
    Iyidir, Ozlem Turhan
    Bozkus, Yusuf
    Kirnap, Nazli Guelsoy
    Kut, Altug
    Nar, Asli
    Tutuncu, Neslihan Bascil
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2023, 23 (06) : 826 - 831
  • [18] Insulin aspart in a 30/70 premixed formulation - Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture
    Weyer, C
    Heise, T
    Heinemann, L
    DIABETES CARE, 1997, 20 (10) : 1612 - 1614
  • [19] Distribution and metabolism of the novel rapid-acting insulin analogue insulin Aspart in rats and dogs
    Plum, A
    Hansen, KT
    Andersen, L
    Larsen, UD
    DIABETES, 1999, 48 : A451 - A451
  • [20] Insulin degludec is a new ultra-long-acting insulin analogue
    Dedov, I. I.
    Shestakova, M. V.
    DIABETES MELLITUS, 2014, 17 (02): : 91 - 104
12345